Climb Bio Inc. (CLYM) Dividend Safety Gauge & 10-Year DRIP Compounder

The per the Roarable RQD rating, CLYM carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars, each scored out of 20, are:

• Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -9.19%. This is the weakest pillar and indicates the business is consuming rather than generating cash on a return basis.
• Whale 13F Flow: 6 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is moderate-to-weak, and the source data does not provide the underlying 13F holdings detail.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the second-weakest score, suggesting limited insider-side conviction signals in the rating's inputs.
• Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity read. The score is moderate-to-weak.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, but it is still only half-credit.

Taken together, the pillars indicate that the rating's weakest inputs are operating cash generation and insider conviction, while the balance sheet offers partial support. For a prospective investor evaluating the stock today, the implication is that the rating frames CLYM as high-risk on current fundamentals. Upside drivers would have to come from catalysts that the cash-engine and insider pillars do not yet reflect. Valuation tradeoffs are difficult to assess because the source data lacks earnings-based multiples, so the price of $10.33 cannot be benchmarked against earnings. This is an educational reading of the rating, not personalized financial advice.

Climb Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe specific products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the three listed fiscal years, indicating no reported revenue in the source period. The company's market capitalization is $0.6B per the profile.

Per the SEC financials, the company reported operating losses and net losses in all three periods, with FY 2025 operating loss at $-67.9M and net loss at $-59.9M. Per the Roarable RQD rating, ROIC is -35%, and per the market data, gross, operating, and net margins are each 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Cash declined from $87.2M in FY 2024 to $35.7M in FY 2025 per the SEC financials.

Per the recent news and catalysts feed, six items reference CLYM, all rated YELLOW with a MARKET WIRE impact label. Headlines include a TradingView stock-price report, a Yahoo Finance piece on sector performance versus CLYM, a Seeking Alpha analysis referencing a 12-week dosing interval, a Simply Wall St analyst-forecast page, a Yahoo Finance item reporting a Deutsche Bank initiation at Buy citing an autoimmune pipeline, and an NKyTribune piece describing CLYM as a speculative biotech. The 12-week dosing interval and autoimmune pipeline are the most specific clinical-related references in the feed. Per the Butterfly Supply-Chain Graph, the supply_chain field is NONE, with no butterfly links and no proprietary signals.

• What are the company's specific products, clinical programs, and regulatory milestones, given that the source data references a pipeline and dosing interval but no detail?
• What is the source of reported cash decline and the cash runway implied by FY 2025 cash of $35.7M against a $-54.5M FCF figure?
• Why are EPS, P/E, and EV/EBITDA unavailable, and how should valuation be assessed without earnings-based multiples?
• What drove the 52-week range spanning $1.63 to $18.33, and what institutional or insider activity accompanied that move?
• What is the basis for the Deutsche Bank Buy initiation referenced in the news feed, and does that view appear in the analyst data?